Lv74
5000 积分 2021-06-27 加入
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for EarlyTOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
14天前
已完结
Anthracyclines in Early Breast Cancer: The Long Goodbye
14天前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
18天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
22天前
已完结
CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer
23天前
已完结
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
23天前
已完结
Current Management of Angiosarcoma: Recent Advances and Lessons From the Past
28天前
已完结
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial
29天前
已完结
Thoracic Radiotherapy Improves the Survival in Patients With EGFR -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
30天前
已完结
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
30天前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
2年前
已采纳
滇牡丹花瓣着色过程中类胡萝卜素成分变化和相关基因表达分析
2年前
已采纳
皖公网安备34019202002308
